Bi-functional Molecules Degrade Circulating Proteins via ASGPr
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for autoimmune diseases and cancers mediated by macrophage migration inhibitory factor (MIF) or Immunoglobulin G (IgG) are limited by the need for multiple protein-protein interaction inhibitors and immunogenicity, and lack effective methods for reducing circulating MIF or IgG levels.
Innovation Solution
Development of bi-functional small molecules that selectively bind to MIF or IgG and engage the endo-lysosomal pathway of hepatocytes through the asialoglycoprotein receptor, leading to the degradation and reduction of these proteins, thereby attenuating disease symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antibody-based strategies are used to target MIF or IgG, then therapeutic efficacy is achieved, but immunogenicity increases and manufacturing costs increase
Solution Approach 1:
The patent uses small molecule compounds that copy or mimic the binding capabilities of antibodies against MIF and IgG, but without the immunogenicity of protein-based therapies. The small molecules are designed to bind to the same targets (MIF and IgG) while avoiding the immune system's recognition of foreign proteins.
Solution Approach 2:
The patent employs small molecule compounds that are cheaper to manufacture and have shorter half-lives compared to monoclonal antibodies. These small molecules can be produced through chemical synthesis rather than complex bioprocessing, reducing manufacturing costs and potential immunogenicity.
2Adaptability or versatility
If multiple protein-protein interaction inhibitors are used to target MIF, then therapeutic coverage is improved, but device complexity and treatment complexity increase
Solution Approach 1:
The patent merges multiple therapeutic functions into a single bi-functional small molecule compound. The molecule contains both an MIF-binding motif and an IgG-binding motif, allowing it to simultaneously target both MIF and IgG pathways with one agent, simplifying treatment complexity while maintaining broad therapeutic coverage.
Solution Approach 2:
The bi-functional small molecule exhibits multi-functionality by being capable of binding to both MIF and IgG targets. This universal binding capability allows a single compound to address multiple disease mechanisms that would otherwise require separate inhibitors.
3Ease of manufacture
If bi-functional small molecules are used to target MIF or IgG, then manufacturing costs are reduced and immunogenicity is lowered, but the ability to interrupt multiple protein-protein interactions may be limited
Solution Approach 1:
The bi-functional small molecule is segmented into distinct functional motifs: an MIF-binding motif, an IgG-binding motif, and a linker region. This segmentation allows each motif to independently perform its binding function while being part of a unified molecular structure that can be chemically synthesized.
Solution Approach 2:
The patent creates a composite small molecule structure that combines different binding motifs within a single chemical entity. This composite structure integrates the MIF-binding capability, IgG-binding capability, and linker components into one molecule that can be produced through chemical synthesis rather than biological manufacturing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bi-functional molecules effectively lower plasma MIF or IgG levels, providing a robust therapeutic response with reduced immunogenicity and improved manufacturing costs compared to traditional antibody-based strategies, potentially offering a cure or significant symptom reduction for autoimmune diseases and cancers.
Implementation Method 1
The compounds selectively bind MIF or IgG in plasma and subsequently engage the endo-lysosomal pathway of hepatocytes through ASGPr
Implementation Method 2
MIF or IgG is internalized and degraded by hepatocytes, thus resulting in potential attenuation of corresponding disease symptoms
Data Source
AI summary
The present invention is directed to bi-functional compounds which find use as pharmaceutical agents in the treatment of disease states and/or conditions which are mediated through macrophage migration inhibitory factor (MIF) or immunoglubin G (IgG). The present invention is also directed to pharmaceutical compositions which comprise these bi-functional compounds as well as methods for treating disease states and/or conditions which are mediated through MIF/IgG or where MIF/IgG is a contributing factor to the development and perpetuation of diseases and/or conditions, especially including autoimmune diseases and cancer, among others. The purpose of the present invention is to provide a molecular strategy to lower plasma MIF/IgG level in patients with autoimmune diseases or certain types of cancers. The bi-functional molecule construct is comprised of a MIF/IgG-targeting motif, that is derived from small molecule MIF/IgG ligands, and an ASGPr-targeting motif that binds to hepatocyte asialoglycoprotein receptor (ASGPr). The compounds selectively bind MIF or IgG in plasma and subsequently engage the endo-lysosomal pathway of hepatocytes through ASGPr. As a consequence, MIF/IgG is internalized and degraded by hepatocytes, thus resulting in potential attenuation of corresponding disease symptoms which are modulated through MIF/IgG.